Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

Authors

Parijatham S Thomas
Anisha B Patel
J Jack Lee
Diane D Liu
Mike Hernandez
Miguel Muzzio
Alejandro Contreras
Valerie Sepeda
Carrie Mays
Diane Weber
Lana A Vornik
Seema A Khan
Eileen Dimond
Brandy M Heckman-Stoddard
Marjorie Perloff
Powel H Brown

Publication Date

1-4-2023

Journal

Cancer Prevention Research

DOI

10.1158/1940-6207.CAPR-22-0210

PMID

36228112

PMCID

PMC10391360

PubMedCentral® Posted Date

August 2023

PubMedCentral® Full Text Version

Author MSS

Abstract

Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential chemoprevention agent, for safety and toxicity in high-risk women for breast cancer.

Keywords

Female, Bexarotene, Neoplasms, Humans, Administration, Topical, Antineoplastic Agents

Published Open-Access

yes

Recommended Citation

Thomas, Parijatham S; Patel, Anisha B; Lee, J Jack; et al., "Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer" (2023). Faculty, Staff and Student Publications. 346.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/346